Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister
April 3, 2020
-
BUSINESS Amgen Kicks Off Stand-Alone Biz in Japan, Eyes Simultaneous Launch of Full Pipeline
April 2, 2020
-
BUSINESS Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
-
BUSINESS Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
-
REGULATORY Global Health Confab Issues Proposals for Regulatory Harmonization in Asia
March 31, 2020
-
BUSINESS Daiichi Sankyo Files Yescarta, Second CAR-T Therapy in Japan
March 30, 2020
-
REGULATORY New Stable Supply Panel Wants to Define “Key Drugs” by This Summer
March 30, 2020
-
REGULATORY PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
-
REGULATORY Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate
March 27, 2020
-
REGULATORY Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
-
REGULATORY Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
-
BUSINESS Novartis Japan to Shed Oncology Staffers amid Overall Downscaling
March 24, 2020
-
ACADEMIA Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
-
BUSINESS Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
-
REGULATORY Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
-
BUSINESS (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
-
ACADEMIA Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
-
BUSINESS Post-Promotion Guidelines - 1: Drug Makers Struggling to Establish Non-Sales Criteria for Rep Performance Review
March 18, 2020
-
BUSINESS Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
-
ORGANIZATION Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…